丹参酮注射液对AECOPD血栓前状态的治疗研究

Study of tanshinone as adjuvant treatment in prothrombotic state of AECOPD

目的探讨丹参酮注射液对慢性阻塞性肺病急性发作期(AECOPD)血栓形成前状态治疗的疗效及机制。方法采用病例对照研究的方法,将60例AECOPD患者随机分为对照组(n=30)和丹参酮治疗组(n=30),对照组常规治疗,丹参酮治疗组常规治疗基础上接受丹参酮注射。检测所有患者的血气分析、D-二聚体、血管假性血友病因子(vWF)、凝血酶调节蛋白(TM)、组织因子(TF)、凝血因子X、血栓烷B2(TXB2))、6-酮-前列腺素F1a(6-KPGF1a)。结果治疗后,丹参酮治疗组与对照组比较,PaO2、6-K-PGF1a水平升高,vWF、TM、D-dimer、TF、凝血因子X、TXB2水平降低,差异均有统计学意义(P均<0.05)。结论丹参酮可能通过影响血栓素和前列环素的形成、促血栓形成因子的含量下降来防止AECOPD患者血栓形成、改善缺氧。

Objective To observe the therapeutic effectiveness of tanshinone injection for prothrombotic state of AECOPD and investigate its mechanism. Methods The study was conducted by means of case control study. 30 AECOPD patients with conventional therapy were selected for control group, and 30 AECOPD patients treated with tanshinone were selected for treatment group. Vigour analysis, D-dimer, coagulation factor X, von Willebrand factor, thrombomodulin, tissue factor,TXBz,and 6-K-PGFIa were measured. Results Compared to control group,there were significant higher levels in PaO2 and 6-K-PGFla,and significant lower levels in von Willebrand factor,thrombomodulin,D-dimer,tssue factor,coagulation factor X,and TXB2 （P〈0.05）. Conclusion Tanshinone may redress the prothrombotic state by the corrected to influencing the expression of TXA2 and PGI2.